Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Doxorubicin, Paclitaxel, and Carboplatin in Endometrial Cancer
NCT00006377Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jun 2000
- Primary completion
- Jan 2003
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of doxorubicin, paclitaxel and carboplatin in endometrial cancer (EC), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Response Rate and Duration of Response. Started Jun 2000; status: completed.
02
Drugs
doxorubicinpaclitaxelcarboplatin
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT00006377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006377.